The effect of angiotensin II receptor blocker (ARB) or thiazolidinedione (TZD) on adipocytokines and oxidative stress markers (Senri Study II)

The effect of angiotensin II receptor blocker (ARB) or thiazolidinedione (TZD) on adipocytokines and oxidative stress markers (Senri Study II) - Senri Study II

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000001456

Enrollment

200

Registered

2010-04-01

Start date

2008-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertensive and/or Diabetic patients

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Hypertensive and/or diabetic patients who understand the study procedures using explanatory notes and have given written informed consent to participate in the study, and, 2)Patients have not yet received candesartan and pioglitazone.

Exclusion criteria

Exclusion criteria: 1)Contraindications of candesartan 2)Contraindications of Pioglitazone

Design outcomes

Primary

Measure	Time frame
Changes of TBARS(Thiobarbituric acid reactive substances), highsensitive CRP, and Adiponectin at the completion of treatment form baseline	—

Secondary

Measure	Time frame
Changes of waist circumference, glucose-lipid metabolic parameters, and blood pressure	—

Countries

Japan

Contacts

Public ContactKen Kishida

Osaka University Metabolic medicine

kkishida@imed2.med.osaka-u.ac.jp

Outcome results